Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Partnrs in a research note issued to investors on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Insulet’s Q1 2024 earnings at $0.48 EPS, Q4 2024 earnings at $1.02 EPS, FY2026 earnings at $5.84 EPS and FY2027 earnings at $6.31 EPS.
A number of other equities research analysts have also recently issued reports on PODD. TD Cowen dropped their price objective on Insulet from $350.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 9th. Robert W. Baird lowered Insulet from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $320.00 to $219.00 in a report on Monday, August 21st. Bank of America decreased their price objective on Insulet from $365.00 to $295.00 and set a “buy” rating on the stock in a report on Thursday, August 24th. UBS Group decreased their price objective on Insulet from $270.00 to $215.00 and set a “neutral” rating on the stock in a report on Wednesday, September 6th. Finally, StockNews.com initiated coverage on Insulet in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $262.94.
Get Our Latest Research Report on Insulet
Insulet Price Performance
Insulet (NASDAQ:PODD – Get Free Report) last posted its earnings results on Tuesday, August 8th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.14. Insulet had a return on equity of 22.42% and a net margin of 4.29%. The company had revenue of $396.50 million during the quarter, compared to analyst estimates of $383.97 million. Research analysts expect that Insulet will post 1.64 EPS for the current year.
Insider Buying and Selling at Insulet
In other Insulet news, CEO James Hollingshead bought 5,550 shares of the firm’s stock in a transaction on Monday, August 28th. The shares were purchased at an average price of $181.41 per share, for a total transaction of $1,006,825.50. Following the completion of the transaction, the chief executive officer now directly owns 34,177 shares in the company, valued at approximately $6,200,049.57. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.90% of the company’s stock.
Institutional Trading of Insulet
A number of hedge funds have recently made changes to their positions in PODD. Moneta Group Investment Advisors LLC lifted its stake in shares of Insulet by 101,333.5% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock worth $382,818,000 after acquiring an additional 1,299,095 shares during the period. Gateway Advisory LLC bought a new stake in Insulet during the first quarter worth $550,000. Geode Capital Management LLC grew its holdings in Insulet by 55.4% during the first quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier’s stock worth $473,166,000 after buying an additional 529,926 shares in the last quarter. Clearbridge Investments LLC grew its holdings in Insulet by 38.8% during the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after buying an additional 474,545 shares in the last quarter. Finally, Norges Bank purchased a new position in Insulet in the fourth quarter worth $105,275,000.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
Featured Stories
- Five stocks we like better than Insulet
- Short Selling: How to Short a Stock
- Analysts Recommend These Stocks To Cushion The Automotive Slump
- Upcoming IPO Stock Lockup Period, Explained
- Hyatt Hotels Earning Analysts Love, Buy The Dip?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Business is Good for Lockheed Martin; Shares are Ready to Soar.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
